MedPath

INSTITUTO GRIFOLS SA

🇪🇸Spain
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

87

Active:60
Completed:21

Trial Phases

5 Phases

Phase 1:51
Phase 2:12
Phase 3:10
+2 more phases

Drug Approvals

4

NMPA:2
EMA:2

Drug Approvals

Human Albumin

Product Name
人血白蛋白
Approval Number
国药准字SJ20140106
Approval Date
Sep 14, 2024
NMPA

Human Albumin

Product Name
人血白蛋白
Approval Number
S20140106
Approval Date
Dec 20, 2019
NMPA

Clinical Trials

Distribution across different clinical trial phases (77 trials with phase data)• Click on a phase to view related trials

Phase 1
51 (66.2%)
Phase 2
12 (15.6%)
Phase 3
10 (13.0%)
Phase 4
2 (2.6%)
Not Applicable
1 (1.3%)
phase_1_2
1 (1.3%)

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis

Phase 3
Withdrawn
Conditions
Congenital Afibrinogenemia
Hypofibrinogenemia
First Posted Date
2020-11-19
Last Posted Date
2023-10-23
Lead Sponsor
Instituto Grifols, S.A.
Registration Number
NCT04636268

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Phase 2
Completed
Conditions
COVID-19
Interventions
Biological: Convalescent anti-SARS-CoV-2 MBT Plasma
Drug: Standard Medical Treatment
First Posted Date
2020-09-14
Last Posted Date
2021-03-03
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
200
Registration Number
NCT04547127
Locations
🇪🇸

Hospital General Universitario de Alicante, Alicante, Spain

🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Spain

🇪🇸

Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain

and more 9 locations

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

Phase 2
Completed
Conditions
COVID-19
Interventions
Biological: Prolastin
Drug: Standard Medical Treatment
First Posted Date
2020-07-31
Last Posted Date
2021-07-08
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
100
Registration Number
NCT04495101
Locations
🇪🇸

Hospital Universitario de Burgos, Burgos, Castilla León, Spain

🇪🇸

Hospital Universitari Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Clínic de Barcelona, Barcelona, Spain

and more 6 locations

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

Phase 2
Completed
Conditions
COVID-19
Interventions
Biological: Intravenous Immune Globulin
Drug: Standard Medical Treatment
First Posted Date
2020-06-16
Last Posted Date
2021-03-10
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
100
Registration Number
NCT04432324
Locations
🇪🇸

Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain

🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Del Mar, Barcelona, Spain

and more 7 locations

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

Phase 3
Completed
Conditions
Excessive Bleeding During Surgery
First Posted Date
2018-03-12
Last Posted Date
2023-04-14
Lead Sponsor
Instituto Grifols, S.A.
Target Recruit Count
186
Registration Number
NCT03461406
Locations
🇺🇸

Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

University of Michigan, Michigan Center, Michigan, United States

🇺🇸

The Urological Institute of Northeastern New York, Albany, New York, United States

and more 37 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath